Post-Marketing Safety Signals of Four JAK Inhibitors for Alopecia Areata: An Indication-Restricted FAERS Pharmacovigilance Study
March 2026
in “
Journal of Dermatological Treatment
”
JAK inhibitors tofacitinib baricitinib ruxolitinib ritlecitinib alopecia areata FDA Adverse Event Reporting System neuropsychiatric events autoimmune events thrombocytosis deep vein thrombosis breast cancer pyrexia elevated blood cholesterol gastrointestinal events creatine phosphokinase elevation infections FDA
Studysummary This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on tandfonline.com →